CBD has become quite popular over the last couple of years but despite what you might think, it is only one of the 100+ compounds that have been identified in the Cannabis Sativa L plant. Full Spectrum CBD oil, unlike CBD isolate products, includes a wide range of cannabinoids present in the cannabis or hemp plant. Depending on the condition and what you are looking to achieve, it can provide a greater effect than CBD alone as all the cannabinoids work together in what is known as the entourage effect (more on that later).
It is important that you understand the basics of CBD, too. CBD is just one type of cannabinoid that is found in cannabis. Cannabis contains numerous cannabinoids, and CBD is just one of them. CBD is made from the stalks, leaves, and roots of the cannabis plant, unlike other strains that are all made in different ways. It also does not have any THC oil, which many of cannabis strains do. THC oil can induce sleepiness and a high just like it does in marijuana and weed. THC is also another strain belonging to the cannabis family again much like marijuana, weed, and hemp. Hemp has similar properties as CBD and it is also very much legal around the USA.
The plants are cultivated and then sent for extraction. Some CBD oil-based products come from whole plant extracts. Others are derived from isolates. Whole plant extraction is self-explanatory. The entire plant is part of the process. Those in the medical communities prefer this method. They believe that a broader spectrum of cannabinoids yields during whole plant extraction. According to medical specialists, capturing the entire cannabinoid spectrum stimulates the endocannabinoid system. They call this the “entourage effect.”
If you haven’t been bombarded with CBD marketing or raves about it from friends, get ready. This extract—which comes from either marijuana or its industrial cousin, hemp—is popping up everywhere. There are CBD capsules, tinctures, and liquids for vaping plus CBD-infused lotions, beauty products, snacks, coffee, and even vaginal suppositories. Already some 1,000 brands of CBD products are available in stores—and online in states that don’t have lenient cannabis laws. This is a tiny fraction of what’s to come: The CBD market is poised to exceed $1 billion by 2020, per the Chicago-based research firm Brightfield Group.
We also grow our hemp in close rows, limiting the ability of weeds to establish themselves among our fields. Since we sow our hemp seeds close together, the shade from the fast growing hemp plants inhibit the growth of common weeds, negating the need to use herbicides that could cause contamination. Like with pesticides, we avoid using herbicides because they can affect local biological communities or be absorbed by our hemp plants and transferred residually to our customers.
Cannabidiol (CBD) is a naturally occurring compound found in the resinous flower of cannabis, a plant with a rich history as a medicine going back thousands of years. Today the therapeutic properties of CBD are being tested and confirmed by scientists and doctors around the world. A safe, non-addictive substance, CBD is one of more than a hundred “phytocannabinoids,” which are unique to cannabis and endow the plant with its robust therapeutic profile.
Supercritical CO2 extraction is also the key to understanding more cannabinoids in cannabis like Cannabichromene (CBC) and cannabicitran (CBT) and how they interact with each other (called the Entourage effect). This can lead to increased understanding of marijuana in the medical field, and will also allow growers to come up with more effective, new and exciting strains.
The key difference between hemp and marijuana is that hemp contains practically zero THC. In fact, in order to be classified as hemp, a cannabis plant must contain less than 0.3% THC by volume. This is really important because it’s actually the reason why hemp products are legal to buy, sell, and ship. If they don’t get you high, then why would they be illegal?
In response to the FDA’s historic decision, the Drug Enforcement Administration (DEA) announced in September 2018 that it had removed Epidiolex from Schedule I classification, a category reserved for dangerous drugs with no medical value. Henceforth, Epidiolex would be considered a Schedule V drug, the least dangerous designation under the Controlled Substances Act.
Cannabigerol is known as the stem cell cannabinoid for its role as a precursor to other cannabinoids found in hemp and marijuana. Previously overlooked as a significant cannabinoid, the role of CBG is becoming better understood, and companies like Medical Marijuana, Inc.’s AXIM® Biotechnologies are starting to research its potential. Because most CBG is transformed into other cannabinoids like CBD or THC by the cannabis plant, natural CBG levels are low in most processed cannabis plants.
Yes: CBD extracts can’t always be trusted. A 2017 JAMA paper reported that almost 70 percent of all CBD products sold online do not contain the amount of CBD stated on the label. Of the 84 products bought from 31 different companies, 42 percent contained a higher concentration of CBD oil than the label claimed, and 26 percent of the products contained less than the label claimed. The remainder of products contained the labeled amount—give or take 10 percent.
At least one benefit of CBD is well-supported by science: It can be effective in treating children with rare, genetic seizure disorders. Adults, children and even animals with epilepsy have been shown to benefit from the chemical too, the World Health Organization reports. There's also some evidence that CBD can help with anxiety, says Dr. Robert Carson, an assistant professor of neurology and pediatrics at Vanderbilt University who focuses on children with epilepsy. "In children, especially those with autism spectrum disorders, this may manifest as improved interactions with others," he says. Other preliminary research shows CBD holds promise for conditions including Alzheimer's disease, cancer, psychosis and Parkinson's disease – and is pretty much impossible to abuse or become addicted to, WHO says.
Zuardi, A. W., Crippa, J. A., Hallak, J. E., Bhattacharyya, S., Atakan, Z., Martin-Santos, R., … & Guimarães, F. S. (2012). A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation [Abstract]. Current Pharmaceutical Design, 18(32), 5,131–5,140. Retrieved from https://www.ncbi.nlm.nih.gov/pubmed/22716160